The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evolving frontline treatment strategies in mantle cell lymphoma
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, discusses the future of frontline treatment for mantle cell lymphoma (MCL). He highlights the growing role of BTK inhibitors, the potential for novel approaches such as CAR-T therapy, and the prospect of using prognostic markers to identify patients who may benefit from chemotherapy-free strategies. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
